Novavax reports success for NVX-CoV2373 in pediatric group of phase 3 trial
Novavax said that its Covid-19 vaccine NVX-CoV2373 achieved its primary effectiveness endpoint in the pediatric expansion of its phase 3 PREVENT-19 trial. According to the American biotech company, the recombinant nanoparticle protein-based vaccine has overall shown 80% efficacy overall at a time when the Delta variant was the main circulating strain in the US. The […]